These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26686908)

  • 21. Complement in monoclonal antibody therapy of cancer.
    Rogers LM; Veeramani S; Weiner GJ
    Immunol Res; 2014 Aug; 59(1-3):203-10. PubMed ID: 24906530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting innate immune pathways in cancer immunotherapy: state of the art.
    Mastellos DC
    J BUON; 2009 Sep; 14 Suppl 1():S123-30. PubMed ID: 19785054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization against tumor cell surface complement-regulatory proteins.
    Durrant LG; Spendlove I
    Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement in cancer and cancer immunotherapy.
    Kolev M; Towner L; Donev R
    Arch Immunol Ther Exp (Warsz); 2011 Dec; 59(6):407-19. PubMed ID: 21960413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Back to the future - non-canonical functions of complement.
    Kemper C; Köhl J
    Semin Immunol; 2018 Jun; 37():1-3. PubMed ID: 29857931
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent progress in the understanding of complement activation and its role in tumor growth and anti-tumor therapy.
    Liu XY; Wang XY; Li RY; Jia SC; Sun P; Zhao M; Fang C
    Biomed Pharmacother; 2017 Jul; 91():446-456. PubMed ID: 28477461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
    Helfand SC; Hank JA; Gan J; Sondel PM
    Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The complement system in systemic autoimmune disease.
    Chen M; Daha MR; Kallenberg CG
    J Autoimmun; 2010 May; 34(3):J276-86. PubMed ID: 20005073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The delicate balance of macrophages in colorectal cancer; their role in tumour development and therapeutic potential.
    Braster R; Bögels M; Beelen RH; van Egmond M
    Immunobiology; 2017 Jan; 222(1):21-30. PubMed ID: 26358365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viral-derived complement inhibitors: current status and potential role in immunomodulation.
    Abou-El-Hassan H; Zaraket H
    Exp Biol Med (Maywood); 2017 Feb; 242(4):397-410. PubMed ID: 27798122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracellular complement - the complosome - in immune cell regulation.
    Arbore G; Kemper C; Kolev M
    Mol Immunol; 2017 Sep; 89():2-9. PubMed ID: 28601357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement Proteins as Soluble Pattern Recognition Receptors for Pathogenic Viruses.
    Murugaiah V; Varghese PM; Beirag N; De Cordova S; Sim RB; Kishore U
    Viruses; 2021 May; 13(5):. PubMed ID: 34063241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?
    Schwartz-Albiez R; Laban S; Eichmüller S; Kirschfink M
    Autoimmun Rev; 2008 Jun; 7(6):491-5. PubMed ID: 18558368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic inhibition of human cell-mediated cytotoxicity by complement component antisera indicates that target cell lysis may result from an enzymatic cascade involving granzymes and perforin.
    Brahmi Z; Csipo I; Bochan MR; Su B; Montel AH; Morse PA
    Nat Immun; 1995 Sep; 14(5-6):271-85. PubMed ID: 8933821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.
    Melis JP; Strumane K; Ruuls SR; Beurskens FJ; Schuurman J; Parren PW
    Mol Immunol; 2015 Oct; 67(2 Pt A):117-30. PubMed ID: 25697848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic antibodies in oncology: an immunopharmacological overview.
    Toledo-Stuardo K; Ribeiro CH; González-Herrera F; Matthies DJ; Le Roy MS; Dietz-Vargas C; Latorre Y; Campos I; Guerra Y; Tello S; Vásquez-Sáez V; Novoa P; Fehring N; González M; Rodríguez-Siza J; Vásquez G; Méndez P; Altamirano C; Molina MC
    Cancer Immunol Immunother; 2024 Oct; 73(12):242. PubMed ID: 39358613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement system's role in cancer and its therapeutic potential in ovarian cancer.
    Bareke H; Akbuga J
    Scand J Immunol; 2018 Jul; 88(1):e12672. PubMed ID: 29734524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dichotomy of complement system: Tumorigenesis or destruction.
    Sinha A; Singh V; Tandon R; Mohan Srivastava L
    Immunol Lett; 2020 Jul; 223():89-96. PubMed ID: 32333965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.